As the SARS-CoV-2 pandemic continues to severely disrupt healthcare systems and economies worldwide, the Oxford/AstraZeneca vaccine is playing a crucial in fighting the virus. Preclinical studies and clinical studies have demonstrated that the vaccine induces a strong immune response and protects against disease with homologous and variant strains of SARS CoV-2.
Efficacy against symptomatic disease is high after two doses of the vaccine, with real-world effectiveness data demonstrating the positive impact vaccination has on preventing hospitalization.
In this webinar, Associate Professor Teresa Lambe will describe the development, testing and immune readout after vaccination with ChAdOx1 nCOV-19/AZD1222. The session also offers a unique opportunity to interact with Professor Lambe through a live Q&A session following her presentation.
- The development of innovative vaccines against emerging pathogens
- How the Oxford AstraZeneca (ChAdOx1 nCoV-19/AZD1222) vaccine was developed and tested
- The use of vaccine platform technologies during the pandemic and the next steps for research
Development and testing of the ChAdOx1 nCoV-19/AZD1222 vaccine - Teresa Lambe speaks on behalf of the COVID vaccine team at Oxford.